AbbVie Inc (NYSE:ABBV) and Xilio Therapeutics, Inc. (NASDAQ:XLO) announced a collaboration and option-to-license agreement to ...
AbbVie signs heavily backloaded $2.1B Xilio biobucks pact in Big Pharma's latest T-cell engager deal
Having kicked off the year with a T-cell engager deal, AbbVie has returned to the modality. | Having kicked off the year with ...
Shares in biotech group Xilio Therapeutics ($XLO) surged over 125% today after it sealed a cancer-fighting deal with AbbVie ...
Shares of Xilio Therapeutics Inc surged 175% on Wednesday in pre-market trading following the announcement of a collaboration and option agreement with pharmaceutical giant AbbVie (NYSE:ABBV) to ...
GlobalData on MSN9d
AbbVie and Xilio to collaborate on antibody-based immunotherapiesAbbVie has entered a partnership and option-to-license agreement with Xilio for tumour-activated, antibody-based ...
The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...
Xilio Therapeutics announces collaboration with AbbVie for tumor-activated immunotherapies, receiving $52 million upfront, extending cash runway to 2026. Xilio Therapeutics, Inc., a clinical-stage ...
Feb. 12, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living ...
Xilio Therapeutics shares took flight in premarket trading Wednesday after the clinical-stage biotechnology company formed a potentially lucrative collaboration with AbbVie that includes an equity ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback